Atopic Dermatitis

These findings highlight dupilumab’s use as a potential treatment option for individuals with prurigo nodularis.

The findings in this analysis indicate that a balanced, infrequent diet including proteins and fats may provide individuals with a potential strategy for management of atopic dermatitis.

Panelists discuss the diagnosis and referral process for patients with pediatric atopic dermatitis (AD) from both the dermatologist and allergy perspectives, including when a child should be referred to a dermatologist and the importance of a multidisciplinary approach to care for optimizing AD management, with insights on the roles each team member plays in patient care.

Panelists discuss the patient journey for patients with pediatric atopic dermatitis (AD) and their caregivers, from initial presentation through to diagnosis, emphasizing the challenges and emotional aspects that families experience throughout the process.

The results of this analysis point to the significance of emotions in the treatment and functional outcomes of those with dandruff.

In this observational cross-sectional study, investigators highlighted the challenges associated with tapering cortisone creams for patients with atopic dermatitis.

These real-life data highlight dupilumab’s efficacy at 16 weeks, with the safety and effectiveness in children with atopic dermatitis continuing to 52 weeks.

This systematic review and meta-analysis highlighted several key findings on use of probiotics as a treatment of pediatric patients with allergies to food.

In this analysis, the investigators sought to assess the ability of a ChatGPT-4-based chatbot in its performance of key functions in a teledermatology platform.

These data highlight current applications of AI and machine learning in aesthetic medicine, looking specifically at studies graded as Level I or II.

The January 15, 2025 SOCS News Update highlights research ongoing/upcoming initiatives and awards, the My Best Winter Skin Campaign, and the TORPEDO program.

Panelists discuss the diagnostic criteria for atopic dermatitis (AD), highlighting challenges in diagnosis due to the disease’s heterogeneity across factors like age, skin color, and other variables, and explore how this complexity can lead to misdiagnosis or late diagnosis; they also share tips for diagnosing AD, determining disease severity, and incorporating patient-reported outcomes into severity assessments, while examining how advances in treatment and understanding have shaped current perspectives on AD severity.

This analysis highlights the transcriptomic patterns of chronic hand eczema, indicating the potential of novel drug targets.

New topline data released by Inmagene indicate positive findings from a phase 2a trial on IMG-007 for moderate-to-severe atopic dermatitis.

This analysis using worldwide data from GBD 2021 indicates that the global burden of eczema in children has gradually risen and has been projected to continue increasing.

Panelists discuss the pathophysiology of atopic dermatitis (AD), focusing on the role of type 2 inflammation, and explore how AD can serve as an entry point to the atopic march in children, leading to other allergic diseases such as food allergies, asthma, and allergic rhinitis, including early indicators that may predict future comorbidities.

These data expanded upon limited real-world data on retention of dupilumab past 2 years of treatment for patients with atopic dermatitis.

These interim data resulted from the JADE REAL study, with 72-week results suggesting rapid improvements in eczema severity for adults and adolescents.

In a recent study, tralokinumab demonstrates effectiveness and safety for treating moderate-to-severe atopic dermatitis in adults who are dupilumab naïve and non-naïve.

Findings suggest an association between food allergies and atopic dermatitis control and persistence.

A study showed parents of children with atopic dermatitis have an increased odds of taking medication to aid sleep.

This interview featured a discussion with Browning regarding his team’s findings prior to the FDA approval of tapinarof cream 1% for atopic dermatitis.

The submission of roflumilast’s supplemental New Drug Application to the FDA by Arcutis follows the conclusion of the INTEGUMENT-PED and INTEGUMENT-OLE studies.

The approval of tapinarof cream (Vtama) for patients aged 2 years and older with eczema follows the positive findings in the ADORING trial program.